Latest News on GEHC

Financial News Based On Company


Advertisement
Advertisement

GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent

https://www.zacks.com/stock/news/2757568/gehc-inks-license-agreement-with-lantheus-for-prostate-imaging-agent
GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.

Trump Administration Review Targets Medical Supply Chain - Becton Dickinson ( NYSE:BDX ) , Baxter Intl ( NYSE:BAX )

https://www.benzinga.com/markets/large-cap/25/09/47874551/trump-administration-commerce-department-investigation-targets-ppe
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports-including PPE, consumables, and medical devices-to assess reliance on foreign suppliers for critical health products.

Is it a Prudent Move to Retain BSX Stock in Your Portfolio for Now?

https://www.zacks.com/stock/news/2756201/is-it-a-prudent-move-to-retain-bsx-stock-in-your-portfolio-for-now
Boston Scientific's acquisitions and WATCHMAN growth fuel optimism, but currency swings and macro pressures weigh on its outlook.

Reasons to Add Labcorp Stock to Your Portfolio Right Now

https://www.zacks.com/stock/news/2755482/reasons-to-add-labcorp-stock-to-your-portfolio-right-now
LH's biopharma lab growth and efficiency gains boost momentum, but currency and macro pressures weigh on its outlook.

Should You Invest $1,000 in GE Stock Right Now?

https://www.fool.com/investing/2025/09/22/should-you-invest-1000-in-ge-stock-right-now/
Investors are excited about GE again... for good reason.
Advertisement

GEHC or A: Which Is the Better Value Stock Right Now?

https://www.zacks.com/stock/news/2754219/gehc-or-a-which-is-the-better-value-stock-right-now
GEHC vs. A: Which Stock Is the Better Value Option?

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

https://www.zacks.com/stock/news/2753851/is-it-a-prudent-move-to-retain-alc-stock-in-your-portfolio-now
Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.

GE HealthCare ( GEHC ) Upgraded to Strong Buy: What Does It Mean for the Stock?

https://www.zacks.com/stock/news/2752944/ge-healthcare-gehc-upgraded-to-strong-buy-what-does-it-mean-for-the-stock
GE HealthCare (GEHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GEHC Expands Women's Health Portfolio With AI-Enabled Voluson

https://www.zacks.com/stock/news/2752592/gehc-expands-womens-health-portfolio-with-ai-enabled-voluson
GE HealthCare debuts AI-powered Voluson Performance ultrasound systems, enhancing women's health imaging with faster, smarter diagnostics.

GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio

https://www.zacks.com/stock/news/2752041/gehc-eyes-icometrix-buyout-to-strengthen-neurology-imaging-portfolio
GE HealthCare moves to strengthen its neurology portfolio by acquiring icometrix, aiming to integrate AI-driven brain MRI solutions into its imaging platforms.
Advertisement

Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?

https://www.zacks.com/stock/news/2751944/is-it-a-prudent-move-to-retain-mygn-stock-in-your-portfolio-now
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.

Here's Why You Should Add NVST Stock to Your Portfolio Right Now

https://www.zacks.com/stock/news/2749890/heres-why-you-should-add-nvst-stock-to-your-portfolio-right-now
Envista's global expansion, strategic acquisitions, and solid solvency boost growth outlook despite FX headwinds.

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

https://www.zacks.com/stock/news/2749888/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now
WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.

Here's Why You Should Add PAHC Stock to Your Portfolio Right Now

https://www.zacks.com/stock/news/2749278/heres-why-you-should-add-pahc-stock-to-your-portfolio-right-now
Phibro Animal Health posts strong Animal Health sales growth, aided by a Zoetis acquisition, while Mineral Nutrition and Performance Products rebound.

GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System

https://www.zacks.com/stock/news/2747815/gehc-stock-gains-following-launch-of-revolution-vibe-ct-imaging-system
GE HealthCare's FDA-cleared Revolution Vibe CT promises faster, AI-driven cardiac imaging with improved clarity, boosting efficiency and patient comfort.
Advertisement

GEHC or A: Which Is the Better Value Stock Right Now?

https://www.zacks.com/stock/news/2746848/gehc-or-a-which-is-the-better-value-stock-right-now
GEHC vs. A: Which Stock Is the Better Value Option?

4 Medical Devices Behemoths to Buy Amid Extensive AI Applications

https://www.zacks.com/stock/news/2741358/4-medical-devices-behemoths-to-buy-amid-extensive-ai-applications
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.

GEHC Positioned for Growth With AI, Global Expansion and Margins

https://www.zacks.com/stock/news/2740343/gehc-positioned-for-growth-with-ai-global-expansion-and-margins
GE HealthCare's Q2 results highlight revenue growth, AI-driven innovation, and global expansion with margin gains and strong demand.

GEHC or A: Which Is the Better Value Stock Right Now?

https://www.zacks.com/stock/news/2730488/gehc-or-a-which-is-the-better-value-stock-right-now
GEHC vs. A: Which Stock Is the Better Value Option?

New Strong Buy Stocks for August 15th

https://www.zacks.com/commentary/2701215/new-strong-buy-stocks-for-august-15th
TEN, ECO, MOS, GEHC and SBFG have been added to the Zacks Rank #1 (Strong Buy) List on August 15, 2025.
Advertisement

SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts

https://www.zacks.com/stock/news/2703118/srdx-stock-up-following-q3-earnings-beat-gross-margin-contracts
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.

Tutor Perini and Crocs have been highlighted as Zacks Bull and Bear of the Day

https://www.zacks.com/stock/news/2702089/tutor-perini-and-crocs-have-been-highlighted-as-zacks-bull-and-bear-of-the-day
Tutor Perini surges on a 386% earnings beat, record $21.1B backlog, and higher 2025 guidance, while Crocs struggles with tariff uncertainty.

DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down

https://www.zacks.com/stock/news/2684598/docs-stock-up-in-pre-market-post-q1-earnings-beat-gross-margin-down
Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.

AMN Stock Slips Despite Q2 Earnings & Revenue Beat, Margins Down

https://www.zacks.com/stock/news/2684544/amn-stock-slips-despite-q2-earnings-revenue-beat-margins-down
AMN Healthcare tops second-quarter 2025 earnings and revenue forecasts, but margins and segment sales face continued pressure.

BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up

https://www.zacks.com/stock/news/2679148/bd-stock-gains-in-pre-market-following-q3-earnings-beat-margins-up
BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.
Advertisement

DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands

https://www.zacks.com/stock/news/2674071/davita-stock-down-despite-q2-earnings-beat-gross-margin-expands
DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.

MASI Stock Slips Despite Q2 Earnings and Revenue Beat, Margins Expand

https://www.zacks.com/stock/news/2674068/masi-stock-slips-despite-q2-earnings-and-revenue-beat-margins-expand
Masimo's second-quarter 2025 performance beats earnings and revenue estimates, expands margins and lifts 2025 outlook.

HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down

https://www.zacks.com/stock/news/2668243/hims-stock-plunges-following-q2-earnings-miss-gross-margin-down
Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and subscriber growth.

INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts

https://www.zacks.com/stock/news/2668232/insp-stock-plunges-despite-q2-earnings-beat-gross-margin-contracts
Inspire Medical tops second-quarter 2025 earnings estimates and posts solid revenue growth, but trims 2025 guidance amid margin pressure.

What Makes GE HealthCare ( GEHC ) a New Strong Buy Stock

https://www.zacks.com/stock/news/2663042/what-makes-ge-healthcare-gehc-a-new-strong-buy-stock
GE HealthCare (GEHC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Advertisement

OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands

https://www.zacks.com/stock/news/2650043/opk-stock-slips-following-q2-earnings-miss-gross-margin-expands
OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.

GEHC vs. BSX: Which Stock Is the Better Value Option?

https://www.zacks.com/stock/news/2649813/gehc-vs-bsx-which-stock-is-the-better-value-option
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies ( GEHC Quick QuoteGEHC - ) and Boston Scientific ( BSX Quick QuoteBSX - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises

https://www.zacks.com/stock/news/2639696/ge-healthcare-q2-earnings-sales-beat-estimates-net-margin-rises
GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.

GE HealthCare Technologies ( GEHC ) Q2 Earnings and Revenues Top Estimates

https://www.zacks.com/stock/news/2637904/ge-healthcare-technologies-gehc-q2-earnings-and-revenues-top-estimates
GE HealthCare (GEHC) delivered earnings and revenue surprises of +16.48% and +0.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?

https://www.zacks.com/stock/news/2629690/should-you-buy-sell-or-hold-ge-healthcare-before-q2-earnings
GEHC leans on Imaging and PDx strength for Q2, but tariff headwinds and margin pressures could test investor confidence.
Advertisement

Valneva ( VALN ) Soars 17.4%: Is Further Upside Left in the Stock?

https://www.zacks.com/stock/news/2612321/valneva-valn-soars-174-is-further-upside-left-in-the-stock
Valneva (VALN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

3 AI-Driven Medical Device Stocks to Watch in 2025

https://www.zacks.com/stock/news/2573185/3-ai-driven-medical-device-stocks-to-watch-in-2025
BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.

SNN vs. GEHC: Which Stock Is the Better Value Option?

https://www.zacks.com/stock/news/2553865/snn-vs-gehc-which-stock-is-the-better-value-option
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew ( SNN Quick QuoteSNN - ) and GE HealthCare Technologies ( GEHC Quick QuoteGEHC - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications

https://www.zacks.com/stock/news/2553699/gehc-stock-gains-post-fdas-nod-for-vizamyls-expanded-indications
GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.

GE HealthCare Stock Slips Despite the Launch of bkActiv S Series

https://www.zacks.com/stock/news/2510751/ge-healthcare-stock-slips-despite-the-launch-of-bkactiv-s-series
GEHC expands its bkPortfolio with the AI-powered bkActiv S Series to advance ultrasound-guided procedures.
Advertisement

GEHC Stock Declines Despite Expansion in Precision Care Capabilities

https://www.zacks.com/stock/news/2503766/gehc-stock-declines-despite-expansion-in-precision-care-capabilities
GE HealthCare integrates proprietary algorithms into MIM Encore to advance digital imaging and workflow precision.

Why Is Perrigo ( PRGO ) Down 3.1% Since Last Earnings Report?

https://www.zacks.com/stock/news/2487646/why-is-perrigo-prgo-down-31-since-last-earnings-report
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Things Nvidia Management Just Said That Build the Buy Case for These 3 Magnificent Hidden AI Stocks

https://www.fool.com/investing/2025/06/04/3-things-nvidia-management-just-said-that-build-th/
Nvidia's ( NASDAQ: NVDA ) recent earnings report boosted the market and alleviated concerns about any slowdown in artificial intelligence ( AI ) and data-center-related spending. That's great news for Nvidia and other frontline players in the AI/data center industry.

Nvidia Unveils Foundation Models For Humanoids, Eyes 'Era of Robotics' As AI Spend Accelerates - GE HealthCare Techs ( NASDAQ:GEHC ) , GE Aerospace ( NYSE:GE )

https://www.benzinga.com/markets/equities/25/05/45662285/nvidia-unveils-foundation-models-for-humanoids-eyes-era-of-robotics-as-ai-spend-accelerates
Nvidia Corp. NVDA unveiled its robotics strategy during its first-quarter 2025 earnings call on Wednesday, positioning the chipmaker for what executives called the emerging "era of robotics" as artificial intelligence expands beyond data centers into physical applications.

GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL

https://www.zacks.com/stock/news/2473038/gehc-stock-may-rise-following-the-launch-of-ai-based-clearecon-dl
GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.
Advertisement

GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use

https://www.zacks.com/stock/news/2471945/ge-healthcare-stock-may-gain-as-fda-approves-optison-for-pediatric-use
GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart diagnostics for children with safer imaging.

Jim Cramer: SoFi Goes To 'New Highs,' Recommends Not Buying This Health Care Stock - Roku ( NASDAQ:ROKU ) , GE HealthCare Techs ( NASDAQ:GEHC )

https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes SoFi Technologies, Inc. SOFI, adding that the stock goes to "new highs." To support his view, the company reported quarterly adjusted sales of $770.72 million on April 29, beating analyst estimates of $739.04 million.

GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech

https://www.zacks.com/stock/news/2468217/gehc-stock-surges-as-signa-sprint-mri-redefines-15t-imaging-tech
GE HealthCare unveils SIGNA Sprint MRI, a high-performance 1.5T system designed to boost diagnostic accuracy, accelerate imaging, and advance cardiac and cancer care.

Here's Why GE HealthCare Stock Blasted Higher Today

https://www.fool.com/investing/2025/05/12/heres-why-ge-healthcare-stock-blasted-higher-today/
A thawing in the U.S./China trading relationship is excellent news for a company like GE HealthCare Technologies ( NASDAQ: GEHC ) . It's a large exporter to China ( a market management sees as having excellent long-term potential ) and uses Chinese-sourced components in its products.

MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know

https://www.zacks.com/stock/news/2462422/medtechs-adjust-2025-outlook-amid-tariffs-what-investors-need-to-know
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement